NCT06544655Active, not recruitingPhase 1
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
A Phase 1/1b First-in-human Trial of BMS-986484 as Monotherapy and Combination Therapy in Participants With Advanced Solid Malignancies
Source: ClinicalTrials.gov · Last updated 17 Apr 2026
Brief summary (registry, in English)
The purpose of this study is to assess the safety and tolerability of BMS-986484 administered alone, in combination with nivolumab in participants with advanced/metastatic solid tumors including non-small cell lung cancer (NSCLC), microsatellite stable (MSS) colorectal carcinoma (CRC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastroesophageal junction adenocarcinoma (G/GEJC), and squamous cell carcinoma of the head and neck (SCCHN).
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 213 (estimated)
- First submitted
- 5 Aug 2024
- Start date
- 10 Oct 2024
- Primary completion date
- 14 Oct 2027
- Lead sponsor
- Bristol-Myers Squibb
- Diseases
- Head and neck cancer, Lung cancer, Pancreatic cancer, Colorectal cancer, Gastric and esophageal cancer
- NCT number
- NCT06544655
- EudraCT number
- 2024-513696-40
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 213
- From 10 Oct 2024 to the primary completion date, 14 Oct 2027
- 9 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of or with active interstitial lung disease or pulmonary fibrosis.
- Active, known, or suspected autoimmune disease.
- Serious uncontrolled medical disorders.
- New onset, non-catheter-associated venous thromboembolism within the past 6 months.
Other
- Other protocol-defined Inclusion/Exclusion criteria apply.
Who the study is looking for
- Locally advanced unresectable, metastatic, or recurrent malignant tumors including non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastroesophageal junction adenocarcinoma (G/GEJC), microsatellite stable colorectal cancer (MSS CRC), and squamous cell carcinoma of the head and neck (SCCHN).
- Must have measurable disease by response evaluation criteria in solid tumors version 1.1 (RECIST v1.1).
- Must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (9)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Darlinghurst | Australia | Unknown status |
| - Coordinator of this site? Confirm its status | Elizabeth Vale | Australia | Unknown status |
| - Coordinator of this site? Confirm its status | Montreal | Canada | Unknown status |
| - Coordinator of this site? Confirm its status | Toronto | Canada | Unknown status |
| - Coordinator of this site? Confirm its status | Grand Rapids | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Los Angeles | United States | Unknown status |
| - Coordinator of this site? Confirm its status | San Antonio | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Sioux Falls | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Tucson | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.